Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS

Key Points

• Puma Biotechnology beat quarterly expectations: EPS was $0.19 versus the $0.04 consensus, while revenue reached $56.5 million compared with estimates of $53 million.
• Nerlynx momentum and profitability improved: Quarterly product revenue rose to $53.6 million, management raised full-year guidance, and Puma reported $8.2 million in net income while becoming debt-free after its final $11.1 million loan payment.
• The outlook remains mixed: Alisertib trials are advancing, but new Nerlynx prescriptions declined sequentially, research and development spending is expected to increase, and analysts maintain a consensus “Hold” rating with a $6 price target.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.15, FiscalAI reports. Puma Biotechnology had a net margin of 11.50% and a return on equity of 21.34%. The business had revenue of $56.50 million during the quarter, compared to the consensus estimate of $53.00 million.

Here are the key takeaways from Puma Biotechnology's conference call:

• NERLYNX revenue and demand improved: Q2 net product revenue rose to $53.6 million from $42.0 million in Q1 and $49.2 million a year ago, while U.S. demand increased 8% sequentially and 11% year over year. Management raised full-year 2026 net product revenue guidance to $205–$209 million.
• Puma reported Q2 GAAP net income of $8.2 million, reversing a $3.8 million loss in Q1, and raised full-year net income guidance to $17–$20 million. The company also made its final $11.1 million loan payment and is now debt-free.
• Alisertib development is progressing, with ALISCA-Breast1 enrollment being narrowed to the 40 mg and 50 mg dose groups and ALISCA-Lung1 now enrolling at 70 mg twice daily. Puma expects to start the combination trial ALISCA-Lung02 in Q3 and provide additional trial data in 2027.
• New prescriptions for NERLYNX declined 6% sequentially, and the company expects higher 2026 R&D spending, up 34%–37% year over year, as clinical trials advance. Q3 net income guidance of $2–$2.5 million is substantially below Q2’s result.
• Full-year royalty guidance was reduced to $19–$22 million from $20–$23 million, partly reflecting a possible late-2026 or 2027 reduction in China royalties if generic NERLYNX reaches a specified market-share threshold.

Puma Biotechnology Stock Up 9.7%

Shares of Puma Biotechnology stock traded up $0.79 on Friday, reaching $8.91. 683,217 shares of the stock were exchanged, compared to its average volume of 315,645. The business has a 50 day moving average price of $7.80 and a two-hundred day moving average price of $7.18. The firm has a market capitalization of $453.52 million, a price-to-earnings ratio of 17.13 and a beta of 1.22. Puma Biotechnology has a twelve month low of $3.05 and a twelve month high of $9.40.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Wall Street Zen cut Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 16th. TD Cowen increased their target price on shares of Puma Biotechnology from $5.00 to $6.00 and gave the company a "hold" rating in a research report on Friday. Finally, Weiss Ratings downgraded Puma Biotechnology from a "hold (c+)" rating to a "hold (c)" rating in a report on Monday, May 11th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $6.00.

Trending Headlines about Puma Biotechnology

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Puma reported earnings of $0.19 per share, above the $0.04 consensus estimate, while revenue reached $56.5 million versus expectations of $53.0 million. Profitability included a 10.69% net margin and 20.30% return on equity. Puma Biotechnology Q2 2026 earnings results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. Puma now expects revenue of $224 million to $231 million, above the approximately $222.5 million analyst consensus. Rising Nerlynx sales and planned milestones for the alisertib program provide additional potential catalysts. PBYI Q2 earnings and raised guidance
• Neutral Sentiment: Management’s outlook was mixed for the next quarter. Third-quarter revenue guidance of $56 million to $59 million is slightly below the $59.4 million consensus estimate, suggesting that near-term growth may be more modest despite the improved full-year outlook. Puma Biotech Q2 earnings and revenue results
• Negative Sentiment: TD Cowen remains cautious. The firm raised its price target from $5 to $6 but maintained a “hold” rating. The revised target still implies roughly 32.7% downside from the referenced $8.91 share price, potentially weighing on investor sentiment after the recent advance. TD Cowen raises Puma Biotechnology price target

Insider Buying and Selling

In other news, Director Jay M. Moyes sold 22,000 shares of the company's stock in a transaction on Friday, June 12th. The shares were sold at an average price of $7.22, for a total value of $158,840.00. Following the sale, the director directly owned 58,322 shares of the company's stock, valued at $421,084.84. This represents a 27.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Alan H. Auerbach sold 44,058 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $8.26, for a total transaction of $363,919.08. Following the completion of the sale, the chief executive officer owned 7,261,671 shares in the company, valued at $59,981,402.46. The trade was a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 132,028 shares of company stock worth $1,006,711 in the last quarter. 22.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PBYI. Barclays PLC grew its stake in shares of Puma Biotechnology by 1.9% in the 4th quarter. Barclays PLC now owns 81,434 shares of the biopharmaceutical company's stock valued at $485,000 after buying an additional 1,553 shares during the period. Cerity Partners LLC lifted its holdings in Puma Biotechnology by 18.2% in the fourth quarter. Cerity Partners LLC now owns 12,072 shares of the biopharmaceutical company's stock valued at $72,000 after acquiring an additional 1,862 shares during the last quarter. BNP Paribas Financial Markets grew its position in Puma Biotechnology by 39.7% in the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company's stock worth $43,000 after acquiring an additional 2,290 shares during the period. First Trust Advisors LP grew its position in Puma Biotechnology by 2.5% in the fourth quarter. First Trust Advisors LP now owns 122,800 shares of the biopharmaceutical company's stock worth $731,000 after acquiring an additional 3,021 shares during the period. Finally, Royal Bank of Canada increased its stake in Puma Biotechnology by 3.8% during the first quarter. Royal Bank of Canada now owns 85,999 shares of the biopharmaceutical company's stock worth $254,000 after acquiring an additional 3,117 shares during the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company's lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source